{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PANVAC-V&page=2", "query": { "intervention": "PANVAC-V", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PANVAC-V&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T01:17:16.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03699124", "title": "Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "FD MVA-BN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 1129, "start_date": "2019-06-19", "completion_date": "2020-06-22", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699124" }, { "nct_id": "NCT02038881", "title": "Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "IMVAMUNE®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 87, "start_date": "2014-04-28", "completion_date": "2017-05-10", "has_results": true, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038881" }, { "nct_id": "NCT00048893", "title": "Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant vaccinia-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2002-11", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-04-13", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048893" }, { "nct_id": "NCT00108732", "title": "A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant Vaccinia-TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2006-02", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2015-06-30", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 7, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108732" }, { "nct_id": "NCT00914732", "title": "Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "MVA Smallpox Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "38 Years", "sex": "ALL", "summary": "18 Years to 38 Years" }, "enrollment_count": 523, "start_date": "2010-02", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 8, "location_summary": "Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 4 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914732" }, { "nct_id": "NCT06075745", "title": "Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "CMV-MVA Triplex", "type": "DRUG" }, { "name": "Placebo for CMV-MVA Triplex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2024-03-05", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 18, "location_summary": "Birmingham, Alabama • La Jolla, California • Redwood City, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075745" }, { "nct_id": "NCT00053508", "title": "Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "ACAM1000", "type": "BIOLOGICAL" }, { "name": "vaccinia virus (calf lymph) smallpox vaccine: Dryvax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "18 Years to 29 Years" }, "enrollment_count": 274, "start_date": "2002-09", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2014-01-22", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 3, "location_summary": "Orlando, Florida • Rochester, Minnesota • Cincinnati, Ohio", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053508" }, { "nct_id": "NCT02326805", "title": "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Prostate Adenocarcinoma AJCC v7", "Stage II Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Rilimogene Galvacirepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 154, "start_date": "2015-06-03", "completion_date": "2022-07-20", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326805" }, { "nct_id": "NCT00001037", "title": "A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp160 Vaccine (Immuno-AG)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 22, "start_date": null, "completion_date": "1995-05", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 2, "location_summary": "St Louis, Missouri • Seattle, Washington", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001037" }, { "nct_id": "NCT00554372", "title": "A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Jennerex Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-26T01:17:16.024Z", "location_count": 5, "location_summary": "La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Billings", "state": "Montana" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00554372" } ] }